- Home
- SELF vs IFRX Comparison
SELF vs IFRX Comparison
Compare SELF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SELF | IFRX |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 86.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SELF | IFRX |
|---|---|---|
| Price | $5.02 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 27.5K | ★ 7.7M |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $12,733,279.00 | $73,729.00 |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | $1,075.42 |
| P/E Ratio | $31.13 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $4.73 | $0.71 |
| 52 Week High | $5.89 | $2.82 |
Technical Indicators
Market Signals| Indicator | SELF | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 42.21 |
| Support Level | $5.03 | $0.92 |
| Resistance Level | $5.17 | $1.28 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 8.70 | 30.42 |
Price Performance
Historical ComparisonAbout SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.